关键词：添加剂预混合饲料行业相关政策、添加剂预混合饲料行业产业链、饲料添加剂产量、饲料添加 剂产值、饲料添加剂营业收入、添加剂预混合饲料行业产量、饲料企业添加剂预混合饲料平均价格、添 加剂预混合饲料行业竞争格局、添加剂预混合饲料行业发展趋势 一、添加剂预混合饲料行业概述 添加剂预混合饲料是以两种（类）或两种（类）以上营养性饲料添加剂为主，与载体或稀释剂按一定比 例配制的饲料，主要包括复合预混合饲料、微量元素预混合饲料及维生素预混合饲料三类。复合预混合 饲料指以矿物质微量元素、维生素、氨基酸中任何两类或两类以上的营养性饲料添加剂为主，与其他饲 料添加剂、载体和（或）稀释剂按所需比例配制的均匀混合物；微量元素预混合饲料指两种或两种以上 矿物质微量元素与载体和（或）稀释剂按所需比例配制的均匀混合物；维生素预混合饲料指两种或两种 以上维生素与载体和（或）稀释剂按所需比例配制的均匀混合物。 添加剂预混合饲料的分类 内容概况：在现代养殖业中，动物营养需求日趋多样化，对饲料性能提出了更高要求，传统标准化产品 已难以满足不同养殖场景的个性化需要。添加剂预混合饲料凭借其灵活的配方设计和精准的营养供给， 有效填补了这一市场空白。 ...

证券日报网讯溢多利（300381）11月25日在互动平台回答投资者提问时表示，截至2025年11月20日，公 司股东人数为20331户。 ...

每经AI快讯，有投资者在投资者互动平台提问：公司目前是否布局水产饲料相关材料业务？包括但不 限于水产饲料用酶制剂、植物提取物、功能性添加剂等产品的研发、生产与销售。同时想了解，公司与 中国农科院合作的"中国水产动物消化道宏基因组计划"是否已落地相关水产饲料材料类成果，后续在该 领域是否有进一步的业务拓展规划？ （文章来源：每日经济新闻） 溢多利（300381.SZ）11月25日在投资者互动平台表示，公司现有水产用酶制剂、水产用植物提取物及 其他水产饲料添加剂产品。公司与中国农科院合作项目的相关产品已落地，在改善水产动物肠道健康方 面发挥了重要作用。公司将持续开展水产用酶制剂及其他水产饲料添加剂相关业务。 ...

格隆汇11月25日丨溢多利(300381.SZ)在投资者互动平台表示，公司现有水产用酶制剂、水产用植物提 取物及其他水产饲料添加剂产品。公司与中国农科院合作项目的相关产品已落地，在改善水产动物肠道 健康方面发挥了重要作用。公司将持续开展水产用酶制剂及其他水产饲料添加剂相关业务。 ...

相关上市企业：溢多利（300381）、蔚蓝生物（603739）、星湖科技（600866）、唐人神（002567）、 新希望（000876）、神农集团（605296）、海大集团（002311）、大北农（002385）、粤海饲料 （001313）、金新农（002548）等。 相关企业：北京昕大洋科技发展有限公司、科明（岳阳）工业科技有限公司、济南天天香有限公司、济 南百斯杰生物工程有限公司、夏盛(北京)生物科技开发有限公司、江苏奕农生物股份有限公司、山东隆 科特酶制剂有限公司、潍坊瑞辰生物科技有限公司等。 关键词：植酸酶行业产业链、植酸酶行业产量、植酸酶行业竞争格局、植酸酶行业发展趋势 一、植酸酶行业相关概述 内容概要：植酸酶作为一种重要的生物酶，在饲料、食品等多个领域有广泛应用。其中饲料领域的需求 增加是推动植酸酶市场增长主要因素，特别是在2020年我国全面禁止饲料中添加抗生素后，植酸酶逐渐 成为抗生素的理想替代品。近年来，随着中国生物技术的快速发展和市场需求的不断扩大，国内植酸酶 的年产量已显著提升。数据显示，2015年中国植酸酶行业产量达到4.32万吨，到了2024年行业产量增长 至12.06万吨。预计未来 ...

Core Points - The Shanghai Composite Index is at 4017.68 points, above the six-month moving average, with a slight decline of 0.29% [1] - A total trading volume of A-shares reached 15648.48 billion yuan today [1] - 113 A-shares have surpassed the six-month moving average, with notable stocks showing significant deviation rates [1] Summary by Category Stock Performance - The top three stocks with the highest deviation rates from the six-month moving average are: - Electric Investment and Financing (9.07%) - Jie Rong Technology (7.54%) - Annie Shares (4.91%) [1] - Other stocks with smaller deviation rates that have just crossed the six-month line include: - Baoland, Zhongnong Lihua, and Subote [1] Trading Data - The trading performance of selected stocks includes: - Electric Investment and Financing: +9.94% with a turnover rate of 2.09% - Jie Rong Technology: +10.00% with a turnover rate of 8.20% - Annie Shares: +6.44% with a turnover rate of 18.47% [1] - Additional stocks with notable performance include: - Yahua Electronics: +6.29% - Zhonglu Shares: +7.08% - Jinlihua Electric: +4.81% [1]

Core Viewpoint - Yidoli is a leading domestic producer of biological enzyme preparations and steroid hormone raw materials, with strong R&D capabilities and a complete industry chain advantage [1] Group 1: Business Overview - Yidoli was established on September 3, 1991, and listed on the Shenzhen Stock Exchange on January 28, 2014, with its registered and office address in Zhuhai, Guangdong Province [1] - The main business includes R&D, production, sales, and services of biological enzyme preparations, steroid hormone raw materials, plant extracts, and animal nutrition and health products, providing comprehensive biotechnology solutions [1] Group 2: Financial Performance - For Q3 2025, Yidoli's operating revenue was 613 million yuan, ranking 27th out of 47 in the industry, significantly lower than the industry leader, Pro Pharmaceutical, which had 7.764 billion yuan, and the second place, Nentek Technology, with 7.13 billion yuan [2] - The net profit for the same period was 19.49 million yuan, ranking 34th in the industry, with a notable gap compared to the industry leader, Zhejiang Pharmaceutical, at 867 million yuan, and Pro Pharmaceutical at 700 million yuan [2] Group 3: Financial Ratios - As of Q3 2025, Yidoli's debt-to-asset ratio was 8.95%, down from 9.68% year-on-year, significantly lower than the industry average of 27.75%, indicating strong solvency [3] - The gross profit margin for the same period was 46.51%, slightly up from 46.43% year-on-year, and higher than the industry average of 35.38%, reflecting strong profitability [3] Group 4: Executive Compensation - Chairman Chen Shaomei's salary for 2024 was 1.1986 million yuan, an increase of 1,900 yuan from 2023 [4] - President Zhou Derong's salary for 2024 was 924,800 yuan, an increase of 2,100 yuan from 2023 [4] Group 5: Shareholder Information - As of September 30, 2025, the number of A-share shareholders was 20,100, with an average holding of 24,400 circulating A-shares, showing no change from the previous period [5] - Among the top ten circulating shareholders, the Guotai Zhongzheng Livestock Breeding ETF ranked as the fourth largest, holding 8.6164 million shares, an increase of 3.0406 million shares from the previous period [5]

Core Insights - Yiduoli (300381.SZ) reported its Q3 2025 results, highlighting a significant increase in institutional investor holdings, which now account for 31.44% of the total shares outstanding [1] Institutional Holdings - As of October 28, 2025, three institutional investors disclosed their holdings in Yiduoli A-shares, totaling 154 million shares [1] - The institutional investors include Zhuhai Jindadi Investment Co., Ltd., Zheshang Bank Co., Ltd. - Guotai Zhongzheng Livestock Breeding ETF, and Zhuhai Juyi Fund Management Co., Ltd. - Juyi Yuer No. 2 Private Securities Investment Fund [1] - The overall institutional holding percentage increased by 0.85 percentage points compared to the previous quarter [1] Public Fund Holdings - One public fund, Guotai Zhongzheng Livestock Breeding ETF, increased its holdings during this period, with an increase percentage of 0.62% [1] - Twelve public funds that were not disclosed in the previous quarter include notable names such as China Merchants Zhongzheng Livestock Breeding ETF and Ping An Zhongzheng Livestock Breeding ETF [1]

Core Insights - The company reported a revenue of 613 million yuan for the first three quarters of 2025, representing a year-on-year growth of 0.77% [1] - The net profit attributable to shareholders decreased by 57.47% to 18.2044 million yuan [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 33.65% to 18.7673 million yuan [1] - The basic earnings per share were 0.0371 yuan [1]

Core Viewpoint - Yiduoli (300381) announced that the company and its subsidiaries do not have overdue debts related to guarantees, are not involved in any litigation guarantees, and have not been judged to bear any liabilities due to guarantees, indicating a stable financial position [1] Group 1 - The company confirmed the absence of overdue debts corresponding to guarantees [1] - There are no litigation-related guarantees involving the company [1] - The company has not been subject to any judgments resulting in liability due to guarantees [1]